Literature DB >> 22707287

Prognostic significance of ATM and cyclin B1 in pancreatic neuroendocrine tumor.

Jae Uk Shin1, Chang Hoon Lee, Kyu Taek Lee, Jong Kyun Lee, Kwang Hyuck Lee, Kwang Min Kim, Kyoung-Mee Kim, Sang-Mo Park, Jong Chul Rhee.   

Abstract

Ataxia telangiectasia mutated kinase (ATM) and cyclin B1 are involved in cell cycle control. The prognostic significance of both molecules has not yet been investigated in pancreatic neuroendocrine tumors. The aim of this study was to evaluate the clinical and prognostic significance of ATM and cyclin B1 in patients with pancreatic neuroendocrine tumors. A total of 107 pancreatic neuroendocrine tumor specimens that were surgically resected were immunohistochemically investigated using the tissue microarray technique. Clinicopathologic results and survival were evaluated retrospectively. High expression of ATM and cyclin B1 was related to well-differentiated endocrine tumors of the World Health Organization (WHO) classification, but not related to TNM stages. The high ATM expression group (ATM ≥ 4) had a significantly smaller tumor size, lower recurrence rate, more number of functioning tumor, and well differentiation of WHO classification. The high cyclin B1 expression group (cyclin B1 ≥ 5) was related to smaller tumor size, less vascular invasion, less recurrence rate, and less death rate. However, cyclin B1 was the only significant factor for survival following multivariate analysis (p = 0.008; OR, 0.54; 95 % CI, 0.35-0.85). The current results suggested that expression of ATM and cyclin B1 may be useful markers to identify patients with poor prognosis who may benefit from close follow-up and aggressive therapy in pancreatic neuroendocrine tumors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22707287     DOI: 10.1007/s13277-012-0420-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  25 in total

1.  Cyclin B1 overexpression and resistance to radiotherapy in head and neck squamous cell carcinoma.

Authors:  Khaled A Hassan; K Kian Ang; Adel K El-Naggar; Michael D Story; Janet I Lee; Diane Liu; Waun K Hong; Li Mao
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

2.  p53 regulates a G2 checkpoint through cyclin B1.

Authors:  S A Innocente; J L Abrahamson; J P Cogswell; J M Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

3.  Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication.

Authors:  J C Soria; S J Jang; F R Khuri; K Hassan; D Liu; W K Hong; L Mao
Journal:  Cancer Res       Date:  2000-08-01       Impact factor: 12.701

4.  Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution.

Authors:  Sara Ekeblad; Britt Skogseid; Kristina Dunder; Kjell Oberg; Barbro Eriksson
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

5.  Expression status of ataxia-telangiectasia-mutated gene correlated with prognosis in advanced gastric cancer.

Authors:  Bin Kang; Rui-Fang Guo; Xiao-Hui Tan; Min Zhao; Zhuo-Bin Tang; You-Yong Lu
Journal:  Mutat Res       Date:  2007-09-01       Impact factor: 2.433

6.  Expression patterns of the ATM gene in mammary tissues and their associations with breast cancer survival.

Authors:  Chuanzhong Ye; Qiuyin Cai; Qi Dai; Xiao-ou Shu; Aesun Shin; Yu-Tang Gao; Wei Zheng
Journal:  Cancer       Date:  2007-05-01       Impact factor: 6.860

Review 7.  Cyclin D1 in human neuroendocrine: tumorigenesis.

Authors:  Daniel C Chung
Journal:  Ann N Y Acad Sci       Date:  2004-04       Impact factor: 5.691

Review 8.  The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification.

Authors:  Günter Klöppel; Aurel Perren; Philipp U Heitz
Journal:  Ann N Y Acad Sci       Date:  2004-04       Impact factor: 5.691

9.  A single ataxia telangiectasia gene with a product similar to PI-3 kinase.

Authors:  K Savitsky; A Bar-Shira; S Gilad; G Rotman; Y Ziv; L Vanagaite; D A Tagle; S Smith; T Uziel; S Sfez; M Ashkenazi; I Pecker; M Frydman; R Harnik; S R Patanjali; A Simmons; G A Clines; A Sartiel; R A Gatti; L Chessa; O Sanal; M F Lavin; N G Jaspers; A M Taylor; C F Arlett; T Miki; S M Weissman; M Lovett; F S Collins; Y Shiloh
Journal:  Science       Date:  1995-06-23       Impact factor: 47.728

10.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

View more
  11 in total

1.  Prognostic value of cyclin B in endometrial endometrioid adenocarcinoma.

Authors:  Simi Santala; Anne Talvensaari-Mattila; Ylermi Soini; Markku Santala
Journal:  Tumour Biol       Date:  2014-10-15

2.  MiR-139-5p Targeting CCNB1 Modulates Proliferation, Migration, Invasion and Cell Cycle in Lung Adenocarcinoma.

Authors:  Bin Bao; Xiaojun Yu; Wujun Zheng
Journal:  Mol Biotechnol       Date:  2022-02-18       Impact factor: 2.860

3.  The prognostic value of Cyclin B1 in pancreatic cancer.

Authors:  Li Zhou; Jian Li; Yu-Pei Zhao; Quan-Cai Cui; Wei-Xun Zhou; Jun-Chao Guo; Lei You; Wen-Ming Wu; Tai-Ping Zhang
Journal:  Med Oncol       Date:  2014-08-09       Impact factor: 3.064

4.  Prognostic Significance of Nuclear Phospho-ATM Expression in Melanoma.

Authors:  Madhuri Bhandaru; Magdalena Martinka; Kevin J McElwee; Anand Rotte
Journal:  PLoS One       Date:  2015-08-14       Impact factor: 3.240

5.  Cyclin b1 suppresses colorectal cancer invasion and metastasis by regulating e-cadherin.

Authors:  Yifeng Fang; Xiao Liang; Wenbin Jiang; Jianbo Li; Junfen Xu; Xiujun Cai
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

6.  Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors.

Authors:  Wen-Chi Chou; Po-Han Lin; Yi-Chen Yeh; Yi-Ming Shyr; Wen-Liang Fang; Shin-E Wang; Chun-Yu Liu; Peter Mu-Hsin Chang; Ming-Han Chen; Yi-Ping Hung; Chung-Pin Li; Yee Chao; Ming-Huang Chen
Journal:  Int J Biol Sci       Date:  2016-11-25       Impact factor: 6.580

Review 7.  Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.

Authors:  E T Aristizabal Prada; C J Auernhammer
Journal:  Endocr Connect       Date:  2017-11-16       Impact factor: 3.335

Review 8.  Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology.

Authors:  Mark Kidd; Irvin M Modlin; Lisa Bodei; Ignat Drozdov
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2015-01-12

9.  Prognostic value of discs large homolog 7 transcript levels in prostate cancer.

Authors:  Christian R Gomez; Farhad Kosari; Jan-Marie Munz; Claire A Schreiber; Gaylord J Knutson; Cristiane M Ida; Abdelouahid El Khattouti; R Jeffrey Karnes; John C Cheville; George Vasmatzis; Stanimir Vuk-Pavlović
Journal:  PLoS One       Date:  2013-12-09       Impact factor: 3.240

Review 10.  From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell?

Authors:  Giovanni Vitale; Alessandra Dicitore; Luigi Barrea; Emilia Sbardella; Paola Razzore; Severo Campione; Antongiulio Faggiano; Annamaria Colao; Manuela Albertelli; Barbara Altieri; Filomena Bottiglieri; Federica De Cicco; Sergio Di Molfetta; Giuseppe Fanciulli; Tiziana Feola; Diego Ferone; Francesco Ferraù; Marco Gallo; Elisa Giannetta; Federica Grillo; Erika Grossrubatscher; Elia Guadagno; Valentina Guarnotta; Andrea M Isidori; Andrea Lania; Andrea Lenzi; Fabio Lo Calzo; Pasquale Malandrino; Erika Messina; Roberta Modica; Giovanna Muscogiuri; Luca Pes; Genoveffa Pizza; Riccardo Pofi; Giulia Puliani; Carmen Rainone; Laura Rizza; Manila Rubino; Rosa Maria Ruggieri; Franz Sesti; Mary Anna Venneri; Maria Chiara Zatelli
Journal:  Rev Endocr Metab Disord       Date:  2020-09-15       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.